Abstract: A composition for use in a method of regulating or treating a metabolic disease or a symptom thereof, the composition comprising an isolated bacteria Lactobacillus brevis (DPC6108) deposited with the National Collection of Industrial and Marine Bacteria Limited (NCIMB) on 28 Nov. 2011 and accorded the accession number NCIMB 41903.

Abstract: A composition for use in a method of regulating or treating a metabolic disease or a symptom thereof, the composition comprising an isolated bacteria Lactobacillus brevis (DPC6108) deposited with the National Collection of Industrial and Marine Bacteria Limited (NCIMB) on 28 Nov. 2011 and accorded the accession number NCIMB 41903.

Abstract: Recombinant human FMR1 constructs and related methods for treating Fragile X syndrome and related disorders in a subject are provided.

Abstract: The disclosure provides for optimized therapeutic MECP2 polynucleotide constructs utilized for replacing or compensating for the loss of MeCP2 function in patients with Rett Syndrome. Suitably, the disclosure provides gene therapy cassettes to enable better regulatory control of the MeCP2 protein, including tunable systems that allow MECP2 gene therapy to be expressed at a desired moderate level and demonstrate expression of the vector-derived transgene within a window that alleviates the disease-causing genetic deficiency without producing undesired side effects including overexpression toxicity.

Abstract: The present disclosure provides compositions comprising Lactobacillus mucosae and soluble dietary fiber, and methods treatment related thereto, useful against metabolic syndrome and related diseases, disorders and morbidities.

Abstract: Disclosed herein are compositions and methods for preventing, ameliorating, or treating Clostridium difficile infections and/or reducing the severity of one or more risk factors, signs, or symptoms associated with C. difficile infections. In particular, the technology of the present disclosure relates to methods for administering an effective amount of a composition comprising strains of Bacillus amyloliquefaciens bacteria identified as ART24, ART4, and ART 12, to a subject suffering from or at risk for C. difficile infections.

Abstract: A system to limit the expression of a vector-derived transgene within a window that alleviates the disease-causing genetic deficiency without producing overexpression toxicity is described. This provides for ‘dosage-insensitivity’, whereby cells or tissues receiving more vector-derived transgene are disproportionately suppressed through an in-built single gene circuit that can regulate adaptively.

Abstract: Disclosed herein are compositions and methods for preventing, ameliorating, or treating Clostridium difficile infections and/or reducing the severity of one or more risk factors, signs, or symptoms associated with C. difficile infections. In particular, the technology of the present disclosure relates to methods for administering an effective amount of a composition comprising strains of Bacillus amyloliquefaciens bacteria identified as ART24, ART4, and ART 12, to a subject suffering from or at risk for C. difficile infections.

Abstract: A medical imaging device comprising: an optical imaging module which generates an image of a region of a body part by acquiring image samples at respective sample locations in the region and mapping the samples to corresponding image pixels; a control module which controls the optical imaging module to acquire a first sequence of samples whose corresponding pixel locations follow a path which is spanned by pixels corresponding to the first sequence of samples and extends over a greater portion of the image than an arrangement in an array of a sequence of pixels corresponding to a second sequence of samples that the optical imaging module is operable to acquire, wherein a sum of distances between adjacent pixels in the sequence of pixels is equal to a length of the path; and a registration module which registers the image against a reference image.

Abstract: Disclosed herein are compositions and methods for preventing, ameliorating, or treating Clostridium difficile infections and/or reducing the severity of one or more risk factors, signs, or symptoms associated with C. difficile infections. In particular, the technology of the present disclosure relates to methods for administering an effective amount of a composition comprising strains of Bacillus amyloliquefaciens bacteria identified as ART24, ART4, and ART 12, to a subject suffering from or at risk for C. difficile infections.

Abstract: A composition for use in a method of regulating or treating a metabolic disease or a symptom thereof, the composition comprising an isolated bacteria Lactobacillus brevis (DPC6108) deposited with the National Collection of Industrial and Marine Bacteria Limited (NCIMB) on 28 Nov. 2011 and accorded the accession number NCIMB 41903.

Abstract: Disclosed herein are compositions and methods for preventing, ameliorating, or treating Clostridium difficile infections and/or reducing the severity of one or more risk factors, signs, or symptoms associated with C. difficile infections. In particular, the technology of the present disclosure relates to methods for administering an effective amount of a composition comprising strains of Bacillus amyloliquefaciens bacteria identified as ART24, ART4, and ART 12, to a subject suffering from or at risk for C. difficile infections.

Abstract: The current invention provides use of a CLA-producing bacterium for the in vivo conversion in the gut of polyunsaturated fatty acids to CLA. The CLA-producing bacterium is selected from one or more of the group consisting of propionibacteria, lactobacilli, lactococci and streptococci, and bifidobacteria.

Abstract: A composition, method and device for the preparation of biological samples for subsequent LC-MS analysis using a combined and concurrent protein precipitation and solid phase extraction (SPE) process is described. Through an integrated combination of protein precipitation, filtration, and SPE using a novel zirconia-coated chromatographic media, interfering compounds, such as proteins and phosphate-containing compounds, are eliminated from the biological samples, affording a higher degree of analyte response during LC-MS analysis.

Abstract: A composition comprises a cohort of at least five isolated unique strains of a single species of bacteria, wherein the species of bacteria is represented in the mammalian microbiome, and wherein the cohort of isolated strains exhibit different and diverse catabolic capability thereby increasing the chances that one or more of the strains in the composition will find a nutritional niche in the infant GI tract.

Abstract: A medical imaging device comprising: an optical imaging module which generates an image of a region of a body part by acquiring image samples at respective sample locations in the region and mapping the samples to corresponding image pixels; a control module which controls the optical imaging module to acquire a first sequence of samples whose corresponding pixel locations follow a path which is spanned by pixels corresponding to the first sequence of samples and extends over a greater portion of the image than an arrangement in an array of a sequence of pixels corresponding to a second sequence of samples that the optical imaging module is operable to acquire, wherein a sum of distances between adjacent pixels in the sequence of pixels is equal to a length of the path; and a registration module which registers the image against a reference image.

Abstract: Methods and apparatus for automatic game generation are described. The method may include receiving, from a first video game console, a first game play result of a first user playing a video game; receiving, from a second video game console, a second game play result of a second user playing the video game; producing, by comparing the first game play result with the second game play results, a message comprising a recommendation for the first user to improve a future game play result over the first game play result, wherein the message further references the second game play result; and communicating the recommendation to the first user.

Abstract: The current invention provides use of a CLA-producing bacterium for the in vivo conversion in the gut of polyunsaturated fatty acids to CLA. The CLA-producing bacterium is selected from one or more of the group consisting of propionibacteria, lactobacilli, lactococci and streptococci, and bifidobacteria.

Abstract: Methods and apparatus for automatic game generation are described. The method may include receiving, from a first video game console, a first game play result of a first user playing a video game; receiving, from a second video game console, a second game play result of a second user playing the video game; producing, by comparing the first game play result with the second game play results, a message comprising a recommendation for the first user to improve a future game play result over the first game play result, wherein the message further references the second game play result; and communicating the recommendation to the first user.

Abstract: Methods and apparatus for automatic game generation are described. The method may include collecting, by a hardware processor of a server over a network, first information associated with a first video game player, second information associated with a second video game player related to the first video game player, and a plurality of events that the first video game player and the second video game player have participated in. The method may also include creating a comparison tree for each of a plurality of event types associated with the plurality of events. The method may further include evaluating the comparison tree against a plurality of video game results to determine outcomes that are satisfied, and for each of the outcomes, generating a plurality of templates.